Factors associated with achieving minimally symptomatic status by patients with schizophrenia: Results from the 3-year intercontinental schizophrenia outpatients health outcomes study

International Journal of Clinical Practice

Volumn 64, Issue 6, 2010, Pages 697-706

  Treuer, T ^a,b   Martenyi, F ^b   Saylan, M ^c   Dyachkova, Y ^a  

^a Eli Lilly Regional GmbH   (Austria)

^b ELI LILLY AND COMPANY   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGE; ARTICLE; BIOGEOGRAPHIC REGION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; PROBABILITY; RISK FACTOR; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950669105     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02331.x     Document Type: Article

References (33)

1. Auslander LA, Jeste DV. Sustained remission of schizophrenia among community-dwelling older outpatients. Am J Psychiatry 2004 161 : 1490 1493.
2. James RL, May PR. Diagnosing schizophrenia: professor Kraepelin and the research diagnostic criteria. Am J Psychiatry 1981 138 : 510 504.
3. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994 151 : 1409 1416.
4. Bleuler M. The Schizophrenic Disorders: Long-Term Patient and Family Studies (1972).
5. Modestin J, Huber A, Satirli E, Malti T, Hell D. Long-term course of schizophrenic illness: Bleuler's study reconsidered. Am J Psychiatry 2003 160 : 2202 2208.
6. Harrison G, Hopper K, Craig T et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001 178 : 506 517.
7. Craig TJ, Siegel C, Hopper K, Lin S, Sartorius N. Outcome in schizophrenia and related disorders compared between developing and developed countries. A recursive partitioning re-analysis of the WHO DOSMD data. Br J Psychiatry 1997 170 : 229 233.
8. Harding CM. Course types in schizophrenia: an analysis of European and American studies. Schizophr Bull 1988 14 : 633 643.
9. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004 161 : 473 479.
10. Bassett AS, Addington D. Canadian clinical practice guidelines for the treatment of schizophrenia. (The Canadian Psychiatric Association). Can J Psychiatry 1998 43 (Suppl. 2 25S 40S.
11. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998 24 : 1 10.
12. Kennedy A, Jain S, Vinogradov S. Atypical antipsychotics for schizophrenia: their collective role and comparative profiles. Formulary 2001 36 : 500 517.
13. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002 16 : 23 45.
14. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003 28 (Suppl. 1 9 26.
15. Schillevoort I, De Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother 2001 35 : 1517 1522.
16. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999 35 : 51 68.
17. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 1223.
18. Frank E, Prien RF, Jarrett RB et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991 48 : 851 855.
19. Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005 162 : 441 449.
20. Van OS J, Drukker M, à Campo J, Meijer J, Bak M, Delespaul P. Validation of remission criteria for schizophrenia. Am J Psychiatry 2006 163 : 20000 20002.
21. Beasley CM Jr., Sutton VK, Hamilton SH et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003 23 : 582 594.
22. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009 438 : 7 14.
23. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000 342 : 1878 1886.
24. Dossenbach M, Pecenak J, Szulc A et al. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. J Clin Psychiatry 2008 69 : 1901 1915.
25. Dossenbach M, Erol A, El Mafoud Kessaci M et al. Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone and haloperidol. J Clin Psychiatry 2004 65 : 312 321.
26. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines.
27. Jager M, Messer T, Laux G et al. Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measures. Pharmacopsychiatry 2008 41 : 190 195.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn.
29. Dossenbach M, Arango-Davila C, Silva Ibarra H et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005 66 : 1021 1030.
30. Lima MS, Soares BG, Paoliello G et al. The Portuguese version of the Clinical Global Impression-Schizophrenia Scale: validation study. Rev Bras Psiquiatr 2007 29 : 246 249.
31. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001 158 : 518 526.
32. Cox DR, Oakes D. Analysis of Survival Data.
33. Haro JM, Kamath SA, Ochoa S et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003 416 : 16 23.